Search clinical trials for: 9 mg/kg GSK2402968

Total 822 results

GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
GlaxoSmithKline

Completed

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) (DMD114876)

Muscular Dystrophies

United States
GlaxoSmithKline

Completed

A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD114044)

Muscular Dystrophies

France, Denmark, Germany, Belgium, Spain, Turkey, Korea, Republic of, Brazil, Netherlands, Italy, Chile, Japan, Canada, Hungary, Russian Federation, Czechia, Poland, Norway, Argentina, Taiwan
BioMarin Pharmaceutical

Terminated

Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Belgium, Netherlands, Italy, Sweden
Sameem M. Abedin, MD

Recruiting

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

Graft-versus-host Disease

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
BioMarin Pharmaceutical

Terminated

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Netherlands, Belgium, Italy, Sweden
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Terminated

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Asthma

United States
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

Asthma

Canada
Eisai Inc.
Dr. Reddy's Laboratory; Citius Pharmaceuticals

Completed

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Persistent or Recurrent Cutaneous T-Cell Lymphoma

United States, Australia, Puerto Rico
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States
Providence Health & Services

Completed

α-TEA in Advanced Cancer

Metastatic Sarcoma | Metastatic Carcinoma | Metastatic Lymphoma

United States
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Eisai Inc.
Biogen

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
BioMarin Pharmaceutical

Terminated

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, Netherlands, France, United Kingdom, Italy
Bill & Melinda Gates Medical Research Institute

Recruiting

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Malaria

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Duke University
National Heart, Lung, and Blood Institute (NHLBI); American Heart Association

Completed

Ketone Pharmacokinetic Study in HFrEF

Heart Failure With Reduced Ejection Fraction

United States
Lpath, Inc.

Completed

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Healthy Subjects

United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (CADENCE)

Hypertension, Pulmonary

United States, Belgium, France, Germany, Israel, Italy, Spain, Sweden, United Kingdom, Poland, Canada
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
CARE Pharma Shanghai Ltd.

Recruiting

A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH

Hemolysis | PNH

China
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Asthma

United States, Canada
aTyr Pharma, Inc.
Foundation for Sarcoidosis Research

Completed

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States
GPCR Therapeutics, Inc.

Completed

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin Lymphoma

Taiwan
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Cubist Pharmaceuticals LLC

Completed

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Proven or Suspected Gram-negative Bacterial Infection | Peri-operative Prophylaxis
Ludwig Institute for Cancer Research
Daiichi Sankyo Co., Ltd.; Austin Health

Completed

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (LUD2014-002)

Malignant Solid Tumor | Metastatic EphA2 Positive Cancer

Australia
Bausch Health Americas, Inc.

Completed

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
ReAlta Life Sciences, Inc.

Withdrawn

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

COVID-19 | Acute Lung Injury | ALI

United States

Search clinical trials for: 9 mg/kg GSK2402968

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations